Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses ceftazidime-avibactam and its uses.
Interview Transcript (slightly modified for readability)
“Ceftazidime-avibactam (Avycaz) is [an interesting] antibiotic [that] was just approved in 2015. What’s [interesting] about it is that it was approved based on phase II data, which is not typical of antibiotics – we usually wait until [there is] phase III data, which means that it is being tested in patients. It was basically approved off of a lot of in-vitro data, partly because ceftazidime itself, which is a component of the antibiotic, has been approved for decades, so we know the safety of that drug.
Seeing these in-vitro results of ceftazidime-avibactam against gram-negative infections was promising. The problem is we have a lot of gram-negative resistance right now, [meaning] a lot of gram-negative organisms have developed resistance to most of the antibiotics that we have. We have something called CRE infections, or carbapenem-resistant Enterobacteriaceae infections or carbapenem-resistant pseudomonal infections. Those pose a huge threat to public health, so we need new antibiotics; [therefore], the FDA and the government are trying to approve antibiotics faster, [and] this is one of those antibiotics.
It’s a [very interesting] agent. We’re hoping that it’s going to work really well for these [extremely] resistant organisms. The other [interesting] thing about it is the avibactam component, which is the beta-lactamase inhibitor is reversible, whereas others that have been approved in the past aren’t. Once it’s kind of done its job, it can go back and work again. It’s a pretty [great] antibiotic that we’re hoping is going to do a lot of good things.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512